NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $50.76 -0.70 (-1.36%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$51.67 +0.91 (+1.80%) As of 11/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cytokinetics Stock (NASDAQ:CYTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytokinetics alerts:Sign Up Key Stats Today's Range$50.60▼$53.4550-Day Range$50.76▼$72.4552-Week Range$50.32▼$88.31Volume1.43 million shsAverage Volume2.08 million shsMarket Capitalization$7.07 billionP/E RatioN/ADividend YieldN/APrice Target$106.50Consensus RatingModerate Buy Company Overview Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries. Founded in 1997, Cytokinetics is based in South San Francisco, California. Its research has focused on translating advances in muscle biology into potential treatments for serious cardiovascular and other muscle-related diseases.AI Generated. May Contain Errors. Read More Cytokinetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCYTK MarketRank™: 2.662730212285 of 5 starsCytokinetics scored higher than 53% of companies evaluated by MarketBeat, and ranked 433rd out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 19 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCytokinetics has a consensus price target of $106.50, representing about 109.8% upside from its current price of $50.76.Amount of Analyst CoverageCytokinetics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($5.85) to ($4.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.21% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 14.15, which indicates bearish sentiment.Change versus previous monthShort interest in Cytokinetics has recently decreased by 3.75%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.03 News SentimentCytokinetics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Cytokinetics this week, compared to 8 articles on an average week.Search Interest5 people have searched for CYTK on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,320,502.00 in company stock.Percentage Held by Insiders2.60% of the stock of Cytokinetics is held by insiders.Percentage Held by InstitutionsCytokinetics has minimal institutional ownership at this time.Read more about Cytokinetics' insider trading history. Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYTK Stock News HeadlinesJPMorgan Chase & Co. Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock PriceNovember 22 at 2:18 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Insider Sells $794,877.72 in StockNovember 21 at 6:14 AM | americanbankingnews.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 22 at 1:00 AM | Porter & Company (Ad)Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $181,230.00 in StockNovember 19 at 7:07 AM | insidertrades.comCytokinetics, Incorporated Announces Prescribing Information For MYQORZO Expanded To Include Data From Phase 3 MAPLE-HCMNovember 17, 2026 | marketscreener.comMCytokinetics (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 Shares of StockNovember 13, 2026 | insidertrades.comCytokinetics (NASDAQ:CYTK) EVP Sells 3,500 Shares of Company StockNovember 4, 2026 | insidertrades.comInsider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $471,075.00 in StockNovember 3, 2026 | insidertrades.comSee More Headlines CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $63.54 on January 1st, 2026. Since then, CYTK stock has decreased by 20.1% and is now trading at $50.7590. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Wednesday, November, 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, topping analysts' consensus estimates of ($1.43) by $0.06. The firm's revenue was up 2356.5% compared to the same quarter last year. Read the conference call transcript. Who are Cytokinetics' major shareholders? Cytokinetics' top institutional shareholders include William Blair Investment Management LLC (1.27%), Pictet Asset Management Holding SA (1.10%), GW&K Investment Management LLC (0.73%) and Fisher Asset Management LLC (0.66%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Sung Lee, Andrew Callos, Wendell Wierenga, Wendall Wierenga, Muna Bhanji, Robert Arthur Harrington, Robert Wong, Edward M Md Kaye, Robert E Landry and B Lynne Parshall. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Novavax (NVAX), Tesla (TSLA), Bristol Myers Squibb (BMY), Salesforce (CRM) and Micron Technology (MU). Company Calendar Last Earnings11/04/2026Today11/22/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, CYTK's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CYTK CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees673Year Founded1998Price Target and Rating Average Price Target for Cytokinetics$106.50 High Price Target$140.00 Low Price Target$84.00 Potential Upside/Downside+109.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($6.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$784.96 million Net Margins-686.63% Pretax Margin-686.63% Return on EquityN/A Return on Assets-48.26% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.36 Sales & Book Value Annual Sales$113.29 million Price / Sales62.41 Cash FlowN/A Price / Cash FlowN/A Book Value($2.31) per share Price / Book-21.97Miscellaneous Outstanding Shares139,303,000Free Float135,681,000Market Cap$7.07 billion OptionableOptionable Beta0.45 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CYTK) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.